Lisinopril/hydrochlorothiazide: Difference between revisions

Revision as of 05:27, 30 August 2011 editBogBot (talk \| contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot ← Previous edit		Revision as of 15:12, 10 September 2011 edit undoPotatoBot (talk \| contribs)Bots51,239 editsm Stub sorting and placement of stub template(s): cardiovascular-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.Next edit →
Line 39:		Line 39:


			{{cardiovascular-drug-stub}}

	{{Antihypertensive-stub}}

Revision as of 15:12, 10 September 2011

Pharmaceutical compound

Lisinopril/hydrochlorothiazide
Combination of
Lisinopril	ACE inhibitor
Hydrochlorothiazide	Thiazide diuretic
Clinical data
MedlinePlus	a601070
Routes of administration	Oral
ATC code	C09BA03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
(verify)

Lisinopril/hydrochlorothiazide (trade name Prinzide by Merck & Co., Zestoretic by AstraZeneca, and many others) is a combination of the drugs lisinopril, an ACE inhibitor, and hydrochlorothiazide, a diuretic. It is used to control hypertension.

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing: Enalapril (+lercanidipine, +nitrendipine) Benazepril (+amlodipine, +pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine, +amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine, +amlodipine and HCT, +HCT) Losartan (+amlodipine, +HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan Telmisartan (+amlodipine, +amlodipine and HCT, +HCT) Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.